(GLOBE NEWSWIRE via COMTEX) — Novartis International AG / Sandoz drives differentiated portfolio with deal to commercialize new treatment fo
Source: www.marketwatch.com
Novartis AG announced that Sandoz has signed an agreement with Japanese pharmaceutical company Shionogi & Co Ltd for the commercialization of Rizmoic (naldemedine) in Germany, UK, and the Netherlands, plus right of first refusal for certain other European markets. Rizmoic (R) is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative. As per the terms of the agreement, Sandoz will commercialize Rizmoic in Germany, the UK and the Netherlands and Shionogi will manufacture and develop the drug. Further details of the deal have not yet been disclosed.
